Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out how to Guarantee Your Dental Embeds Endure forever - 2Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 3This Is Canada's Only Province Without Any Bears
- 4IDF strikes Tehran command centers, weapon production sites
- 5Report: Russian military pressuring students to work as drone pilots
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Vote in favor of your Number one Kind of Gems
- Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- Warning for snow and ice extended
- Fake new headlights rule steer Australian drivers astray
